A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation study based on 3+3 design with the aim to establish MTD and provide
RP2D. PLM60 is to administered by multi-cycle intravenous infusion.